Evidence map›Paper›PMID 27584689›Full record

ArticleJournal of visualized experiments : JoVE2016

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.

Feng Li, Candace Snow-Davis, Chengan Du, Mikhail L Bondarev, Marilyn D Saulsbury, Simone O Heyliger

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feng LiSchool of Pharmacy, Hampton University; FENG.LI@hamptonu.edu.
Candace Snow-DavisSchool of Pharmacy, Hampton University.
Chengan DuSchool of Pharmacy, Hampton University.
Mikhail L BondarevSchool of Pharmacy, Hampton University.
Marilyn D SaulsburySchool of Pharmacy, Hampton University.
Simone O HeyligerSchool of Pharmacy, Hampton University.

Funding

Polymer-drug Conjugate Micelles for Treating Resistant Prostate CancersSC3GM109332 · NIGMS · HAMPTON UNIVERSITY · PI LI, FENG · 2014 to 2016
$333k
NIGMS NIH HHS SC3 GM109332
6 · The paper itself

Abstract

Micelles have been successfully used for the delivery of anticancer drugs. Amphiphilic polymers form core-shell structured micelles in an aqueous environment through self-assembly. The hydrophobic core of micelles functions as a drug reservoir and encapsulates hydrophobic drugs. The hydrophilic shell prevents the aggregation of micelles and also prolongs their systemic circulation in vivo. In this protocol, we describe a method to synthesize a doxorubicin lipophilic pro-drug, doxorubicin-palmitic acid (DOX-PA), which will enhance drug loading into micelles. A pH-sensitive hydrazone linker was used to conjugate doxorubicin with the lipid, which facilitates the release of free doxorubicin inside cancer cells. Synthesized DOX-PA was purified with a silica gel column using dichloromethane/methanol as the eluent. Purified DOX-PA was analyzed with thin layer chromatography (TLC) and (1)H-Nuclear Magnetic Resonance Spectroscopy ((1)H-NMR). A film dispersion method was used to prepare DOX-PA loaded DSPE-PEG micelles. In addition, several methods for characterizing micelle formulations are described, including determination of DOX-PA concentration and encapsulation efficiency, measurement of particle size and distribution, and assessment of in vitro anticancer activities. This protocol provides useful information regarding the preparation and characterization of drug-loaded micelles and thus will facilitate the research and development of novel micelle-based cancer nanomedicines.

Indexed as

Antineoplastic AgentsDoxorubicinDrug CarriersHydrogen-Ion ConcentrationMicellesParticle SizePolymersProdrugsAntineoplastic AgentsDoxorubicinDrug CarriersMicellesPolymersProdrugs

Identifiers

PMID27584689
PMCPMC5091714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.